Emily Bodnar, an analyst at H.C. Wainwright, raised her price target for Purple Biotech Ltd. (NASDAQ:PPBT) from $33 to $34 ...

Purple Biotech (PPBT) has released an update. Purple Biotech Ltd., a clinical-stage bio-pharmaceutical company, is set to present its groundbreaking CAPTN-3 platform at the EORTC-NCI-AACR Symposium.

Purple Biotech shares are trading lower by 27.7% during Tuesday's session. The company announced a $2.8 million offering. Memorial Day Special: Access your full investing command center with ...

Purple Biotech has identified a new serum biomarker, CEACAM1, which may significantly enhance the efficacy of their oncology therapeutic candidate, CM24, for treating metastatic pancreatic cancer.

26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal ...

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company's oncology ...